William M. Sikov, MD, on the CALGB 40603 Trial

2014 San Antonio Breast Cancer Symposium
Tweet this page

William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."

Advertisement

Advertisement



Jun
23
Today In Oncology
FDA Grants Priority Review to Expanded Use of Gardasil 9 in Women and Men Aged 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
Statement From FDA Commissioner on Agency Efforts to Advance the Patient Voice in Medical Product Development and Regulatory Decision-Making
AMA Plans Advocacy Outreach to Expand Colorectal Screening
Ibrutinib in Relapsed or Refractory Follicular Lymphoma
Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML
View More 
;
Advertisement
© 2018 HSP News Service, L.L.C.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.